PUBLICATIONS
Therapies With No Compromise
Phase 1a dose-escalation study of RS-0139: A novel tumor-targeted nanomedicine for advanced solid tumors
ASCO 2025
RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
ESMO TAT 2023
Phase Ia/Ib study of RS-0139 a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer
ESMO 2022
